Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Voriconazole - applications and perspectives].

M Ruhnke1

  • 1Medizinische Klinik und Poliklinik II, Charité Campus Mitte, Humboldt-Universität zu Berlin, Schumannstrasse 20/21, 10117 Berlin, Deutschland. markus.ruhnke@charite.de

Mycoses
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Annals of hematology·2017
Same author

[Spectrum of pathogens in postoperative complications of visceral surgery : The problem of multidrug resistance].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017
Same author

Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Geburtshilfe und Frauenheilkunde·2016
Same author

CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia.

Annals of hematology·2016
Same journal

Pioneer of Medical Mycology: In Memory of Prof. Friedrich Staib, MD, DVM.

Mycoses·2026
Same journal

Insights Into the Susceptibility of Fungal Infection and STAT3 Genetic Mutations.

Mycoses·2026
Same journal

The Underestimated Role of Environmental Factors in the Prevention of Invasive Fungal Disease: Experience From a European Childhood Cancer Centre.

Mycoses·2026
Same journal

Correction to 'Seroprevalence Screening of Chronic Aspergillus Infection in a Post-Tuberculosis Cohort in Senegal: A Cross-Sectional Study Comparing ELISA and Rapid Diagnostic Tests'.

Mycoses·2026
Same journal

Video-Based Training on Physicians' Proficiency in Invasive Fungal Disease: A Multicentre, Cluster Randomised Controlled Trial.

Mycoses·2026
Same journal

Surgical Outcomes and Exploratory Preoperative Risk Stratification for Invasive Pulmonary Fungal Infections in Paediatric Patients: A Single-Center Retrospective Study.

Mycoses·2026
See all related articles

Voriconazole is a broad-spectrum antifungal triazole drug effective against Candida, Cryptococcus, and Aspergillus species. It offers significant therapeutic progress for invasive fungal infections, showing superior efficacy to amphotericin B for aspergillosis.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Context:

  • Voriconazole (Vfend) represents a significant advancement in antifungal therapy.
  • It belongs to the triazole class of antifungal agents.
  • Invasive fungal infections pose a serious threat, particularly in immunocompromised individuals.

Purpose:

  • To evaluate the in vitro and in vivo efficacy of voriconazole.
  • To assess the clinical effectiveness of voriconazole in treating various fungal infections.
  • To compare voriconazole's efficacy against established antifungal treatments.

Summary:

  • Voriconazole demonstrates broad-spectrum activity against yeasts like Candida species and Cryptococcus neoformans.
  • It exhibits excellent efficacy against molds, including Aspergillus species and endemic fungi such as Histoplasma capsulatum.

Related Experiment Videos

  • Clinical studies confirm its effectiveness in treating oral/esophageal candidosis, and acute/chronic invasive aspergillosis.

    • Impact:

    • Voriconazole offers a new therapeutic option with a favorable safety profile, with most adverse events being manageable and not life-threatening.
    • It represents a significant progress in managing invasive fungal infections.
    • Voriconazole is demonstrably more effective than amphotericin B desoxycholate in treating invasive aspergillosis.